Heart drug vyndaqel tracked in Real-World study
NCT ID NCT04108091
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective Vyndaqel is for people with a rare heart condition called transthyretin amyloid cardiomyopathy. Over 1,200 patients in Japan were followed while taking the drug in regular medical practice. The main goal was to track side effects and survival rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN (TTR) AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.